The foundational rule every device sponsor must understand
Before your team debates whether foreign clinical data can substitute for a US Investigational Device Exemption study, one structural requirement must be on the table: under 21 CFR 812.18(a), a company organized outside the United States cannot itself act as the sponsor of record for an FDA IDE study. A US person or entity must assume that sponsor role, even when the clinical evidence package submitted to FDA consists primarily or entirely of data collected outside the United States. That structural reality shapes every strategic conversation about OUS data versus a US IDE study.
When FDA will accept OUS clinical data
FDA will accept foreign clinical data to support a premarket submission, including a 510(k), De Novo request, or PMA, when that data is applicable to the US population and US medical practice and when the study was conducted in accordance with good clinical practice. Sponsors may use OUS data alongside a US IDE study, or in some cases instead of one, provided the evidence meets FDA's applicability and quality standards and the submission clearly addresses how those standards were satisfied.
What 21 CFR 812.28 actually says
The controlling regulation is 21 CFR 812.28, titled 'Acceptance of data from investigations conducted outside the United States.' The regulation states: 'FDA will accept data from investigations conducted outside of the United States in support of an IDE application or an application for marketing approval or clearance if the data are from investigations conducted in accordance with good clinical practice.'
That sentence carries significant operational weight. 'Good clinical practice' in this context means the study must have been designed, conducted, recorded, and reported in ways that provide assurance the data are credible and that the rights, safety, and welfare of subjects were protected. FDA cross-references international standards, including ISO 14155 for medical device clinical investigations, as a recognized framework for satisfying the GCP requirement under 812.28.
The two applicability conditions FDA requires
Beyond the GCP requirement, FDA articulates two specific conditions that sponsors must address when relying on OUS data:
- Applicability to the US population: The foreign study population must be sufficiently similar to the intended US patient population in terms of demographics, disease prevalence, comorbidities, and relevant biological or physiological factors. If meaningful differences exist, sponsors must assess whether those differences affect the generalizability of the results.
- Applicability to US medical practice: The clinical procedures, standard of care, comparator treatments, and use environment in the OUS study must be sufficiently aligned with how the device would be used in the United States. A study conducted in a healthcare system with dramatically different practice patterns, training standards, or procedural norms may require bridging data or a formal applicability justification.
Sponsors who fail to proactively address both conditions in their submission risk a major deficiency request or an outright request for a US IDE study, regardless of how well the OUS data was collected.
Strategic considerations: OUS data alone, or as a bridge?
The decision to rely exclusively on OUS data, use it as the primary evidence base supplemented by a limited US study, or treat it as bridging data alongside a full US IDE study depends on several intersecting factors. Device classification, the novelty of the technology, the degree of difference between the OUS study population and the US intended use population, and the FDA review division's historical precedent for similar devices all bear on this analysis.
For nonsignificant risk devices, the IDE pathway is abbreviated and the burden of a full US study may not arise at all. For higher risk devices subject to PMA review, FDA's expectations for the depth of the applicability justification rise considerably. Early alignment with FDA through a Pre-Submission meeting is one of the most cost-effective steps a sponsor can take before committing to an OUS-only evidence strategy.
Regardless of the clinical evidence strategy chosen, the requirement that a US person serve as sponsor of record when an IDE application is filed does not change. That obligation carries with it substantive responsibilities for study oversight, adverse event reporting, recordkeeping, and communication with FDA throughout the life of the investigation. Sponsors who underestimate those obligations often encounter compliance gaps that delay their programs at critical milestones. ADB Consulting and CRO Inc. serves as US Sponsor of Record for non-US device companies pursuing FDA clinical study authorization, managing the full scope of sponsor obligations so that your team can remain focused on the science.
To review your OUS data package, assess whether it meets FDA's applicability standards under 812.28, or prepare your IDE or premarket submission strategy, our regulatory team is ready to work with you. Visit our clinical trial services page, use our US Sponsor decision tool to assess whether your program needs a US Sponsor of Record, and download our US Sponsor obligations checklist to prepare your team for what comes next. Book a free discovery call with ADB's regulatory team at adbccro.com to get a candid, expert assessment of where your clinical evidence strategy stands today.
Reviewed November 20, 2026 by ADB's regulatory team.
Frequently asked questions
Can a non-US device company submit an IDE application directly to FDA without a US sponsor?
No. Under 21 CFR 812.18(a), a non-US company cannot itself sponsor an FDA IDE study. A US person or entity must serve as sponsor of record, accepting full legal and regulatory responsibility for the investigation. Non-US companies typically address this by designating a US affiliate, a contract research organization with US sponsor capabilities, or a regulatory consulting firm that formally assumes the sponsor role.
What documentation should a sponsor prepare to demonstrate that OUS data is applicable to the US population?
Sponsors should prepare a formal applicability justification that reviews the demographic and clinical characteristics of the OUS study population against the intended US patient population, assesses differences in standard of care and medical practice, and addresses any bridging analyses or literature support that strengthens the comparability argument. FDA guidance on the use of foreign clinical data, as well as the preamble to the 812.28 rulemaking, provide useful framing for how to structure that justification.
Does using OUS data under 812.28 eliminate the need for a US IDE study entirely?
Not always. Whether OUS data can fully substitute for a US IDE study depends on the device risk classification, the review division's precedent for similar devices, and how well the OUS data addresses the applicability conditions. For some nonsignificant risk devices with well-documented OUS evidence, FDA may accept the foreign data package without requiring a US study. For higher risk devices, FDA may request a US study or a targeted US cohort to bridge the OUS data to the US population. Early engagement with FDA through a Pre-Submission meeting is the most reliable way to assess this question for a specific program.
If this applies to your program, our Clinical Trial Services program walks through the process in detail.
Ready to Navigate the FDA Process with Confidence?
Book a free 30-minute discovery call with ADB's regulatory team to discuss your specific device and situation.
Book a Free Pathway Call